| News Updates |
 |
GlaxoSmithKline's long-acting HIV drug nabs FDA priority review as a preventative option
Fierce Pharma | September 28, 2022
|
|
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study
J Int AIDS Soc. 2022 Sep;25(9):e26006. doi: 10.1002/jia2.26006.
|
|
Dolutegravir Offers Superior HIV Suppression in Pregnant Women
Contagion Live | September 14, 2022
|
|
Dolutegravir Compared With Other Regimens for HIV in Pregnancy
Consumer Health News - HealthDay | September 1, 2022
|
|
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States
N Engl J Med. 2022 Sep 1;387(9):799-809. doi: 10.1056/NEJMoa2200600.
|
|
European Commission Approves Once Every 6 Month Supplemental HIV-Treatment
HIV/HCV Watch | August 2022
|
|
Antibiotics Increase Risk for Inflammatory Bowel Disease in Older Adults
Infectious Disease Advisor | August 16, 2022
|
|
Antibiotics Increase Risk for Inflammatory Bowel Disease in Older Adults
Infectious Disease Advisor | August 16, 2022
|
|
Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study
BMC Infectious Diseases - BioMed Central | August 15, 2022
|
|
O’Neill Institute | August 2022
|
|
O’Neill Institute | August 2022
|
|
Fostemavir Improves Outcomes for Treatment-Resistant HIV Patients
Contagion Live | July 30, 2022
|
|
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir
Gilead | July 27, 2022
|
|
Gilead doubles down on HIV prevention, treatment amid Covid setbacks and awaiting FDA decision on long-acting candidate
Endpoints News | July 21, 2022
|
|
On-Demand PrEP Works as Well as Daily Pills
POZ | July 12, 2022
|
|
Long-acting Treatment and Prevention of HIV Are Here
Medscape | July 8, 2022
|
|
GSK's ViiV, under threat from Gilead-Merck collab, eyes 'ultra-long-acting' HIV drugs with ??Halozyme deal
Fierce Pharma | june 22, 2022
|
|
Substantial weight gain as dolutegravir is rolled out in Africa
Aidsmap | June 21, 2022
|
|
ViiV Healthcare looks to make long-acting HIV prevention shot accessible in low
Endpoints News | May 27, 2022
|
|
NHS England is considering off-label use of Descovy PrEP
Aidsmap | May 17, 2022
|
|
POZ | May 17, 2022
|
|
Gilead's HIV prospect lenacapavir escapes FDA hold
Fierce Pharma | May 16, 2022
|
|
FDA approves label update to ViiV's long-acting HIV treatment
Outsourcing Pharma | April 26, 2022
|
|
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
The Lancet | April 20, 2022
|
|
Risk for Incident Liver Damage in Patients With HIV on Antiretroviral Therapy
Infectious Disease Advisor | April 12, 2022
|
|
Counterfeit HIV Drugs: Justice Department Opens Investigation
Medscape | April 11, 2022
|
|
Provider Survey: Prior Authorizations Harm Patients
CANN | April 4, 2022
|
|
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
The Lancet | April 1, 2022
|
|
FDA Approves Triumeq, ViiV Healthcare's Daily Treatment for Children Living With HIV
Contagion Live | March 30, 2022
|
|
ViiV Healthcare announces US FDA approval of Cabenuva for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg
MarketScreener | March 30, 2022
|
|
Uncertain Future for 2 Long-Acting HIV Therapies
Infectious Disease Special Edition | March 30, 2022
|
|
FDA makes oral lead-in optional for long-acting injectable HIV regimen
Healio | March 24, 2022
|
|
Bottlenecks are slowing switch to GSK's long-acting HIV injectable Cabenuva: clinician
Fierce Pharma | March 8, 2022
|
|
FDA rejects Gilead's HIV drug lenacapavir over glass vial concerns
Healio | March 2, 2022
|
|
Evaluation of Sociodemographic Factors and Prevalence of Oral Lesions in People Living with HIV from Cacoal, Rondônia, Amazon Region of Brazil
Int J Environ Res Public Health. 2022 Feb 24;19(5):2614. doi: 10.3390/ijerph19052614.
|
|
Long-acting HIV-1 Capsid Inhibitor Sustained Efficacy in Phase 2/3 Study
Precision Vaccinations | February 19, 2022
|
|
Cabenuva Approved for 2 Month Injections; Insurers Remain a Barrier to Access
Co-infection Watch | February 2022
|
|
HIV: Dual Therapy With Twice-Yearly Injections on the Horizon
Medscape | February 18, 2022
|
|
Antiviral Efficacy, Safety, Tolerability of a Novel HIV-1 Maturation Inhibitor (GSK'254)
Infectious Disease Advisor | January 27, 2022
|
|
Clinical Care Options
|
|
Antimicrobial resistance causes more deaths than HIV and malaria
News Medical | January 22, 2022
|
|
HIV Provider Organization to Launch New Web Resource on Long-Acting Agents
American Academy of HIV Medicine | January 6, 2022
|
|
Dolutegravir-Based Treatment More Effective in Children Living With HIV
Contagion Live | January 6, 2022
|
|
Outcomes of Dolutegravir Treatment in Patients With HIV Infection Who Failed Antiretroviral Therapy
Infectious Disease Advisor | January 5, 2022
|
| |
|
